TABLE 2.
Results of FIC index analysis based on 50%, 25%, and 10% growth endpoints for each group of A. fumigatus azole-resistant and azole-susceptible isolates harboring different or no mutations in cyp51A
| Growth endpoint (%) | Isolates | FIC index (range) |
||||
|---|---|---|---|---|---|---|
| Drugs alone |
Drugs in combinations |
|||||
| MICPOSA | MICCAS | FICimina | CPOSA | CCAS | ||
| 50 | Wild types | 0.03 (0.02–0.03) | 0.5 (0.5–1) | 0.44 (0.19–1.06)* | 0.01 (0.01–0.02) | 0.13 (0.06–0.5) |
| TR group | 0.13 (0.01–0.5) | 0.5 (0.25–1) | 0.27 (0.08–0.76)* | 0.01 (0.01–0.06) | 0.06 (0.06–0.5) | |
| M220 group | 4 (0.02–4) | 1 (0.5–8) | 0.13 (0.05–0.5)* | 0.01 (0.01–1) | 0.13 (0.06–1) | |
| G54/G138 | 4 (0.01–4) | 0.5 (0.13–2) | 0.5 (0.13–0.56)* | 0.01 (0.01–0.25) | 0.06 (0.06–0.5) | |
| HapE | 0.03 (0.01–0.13) | 1 (0.5–8) | 0.25 (0.13–0.62)* | 0.01 (0.01–0.03) | 0.13 (0.06–1) | |
| 25 | Wild types | 0.05 (0.03–0.06) | 8 (1–8) | 0.22 (0.09–0.76)* | 0.01 (0.01–0.02) | 0.5 (0.13–2) |
| TR group | 0.5 (0–1) | 8 (1–8) | 0.13 (0.06–0.52)* | 0.01 (0.01–0.13) | 0.5 (0.06–1) | |
| M220 group | 4 (0.25–4) | 8 (1–8) | 0.25 (0.07–0.5)* | 0.02 (0.01–0.25) | 1 (0.5–2) | |
| G54/G138 | 4 (0.06–4) | 5 (0.5–8) | 0.2 (0.06–1)* | 0.01 (0.01–0.13) | 0.5 (0.06–1) | |
| HapE | 0.13 (0.03–0.5) | 8 (2–8) | 0.16 (0.06–0.62)* | 0.01 (0.01–0.03) | 0.5 (0.13–2) | |
| 10 | Wild type | 0.06 (0.03–0.06) | 8 (8–8) | 0.53 (0.38–0.64)* | 0.02 (0.01–0.03) | 1 (0.06–2) |
| TR group | 0.5 (0.25–1) | 8 (8–8) | 0.52 (0.25–0.75)* | 0.13 (0.06–0.5) | 1 (0.13–2) | |
| M220 group | 1 (0.5–4) | 8 (8–8) | 0.63 (0.31–0.75)* | 0.25 (0.25–0.5) | 2 (1–2) | |
| G54/G138 | 0.25 (0.06–4) | 8 (8–8) | 0.25 (0.19–1.02)* | 0.06 (0.03–1) | 1 (0.06–2) | |
| HapE | 0.13 (0.06–0.5) | 8 (8–8) | 0.5 (0.28–0.56)* | 0.06 (0.02–0.13) | 0.5 (0.25–2) | |
a
*, P < 0.05.